Highlights of the year
- Strong revenue growth of 7% to £42.9m (2009/10: £40.1m)
- Gross profit increased by 10% to £40.2m (2009/10: £36.6m)
Product pipeline
Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors.
Chairman and Chief Executive’s report
‘Continuing the drive to increase revenues and reduce losses, Vectura has delivered another set of robust results, ending the financial year with cash of over £74m. Following the R&D restructuring undertaken in the year, we have focused our pipeline on key respiratory products and consolidated our formulation activities at our Chippenham facility.’
